Tumor infiltrating lymphocyte
Mar 06, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Summary Iovance’s AMTAGVI has become the first personalized TIL therapy to receive regulatory clearance, gaining accelerated FDA approval for use in advanced melanoma following PD-1 inhibitor treatment. AMTAGVI approval has sparked intensified activity across the field, with companies such as Obsidian Therap...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
